XOMA (NASDAQ:XOMA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $123.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research note on Friday, December 27th.

XOMA Stock Down 2.3 %

Shares of NASDAQ XOMA opened at $25.67 on Tuesday. The firm has a market capitalization of $302.47 million, a price-to-earnings ratio of -7.38 and a beta of 0.92. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA has a 52-week low of $18.57 and a 52-week high of $35.00. The stock has a 50 day moving average price of $29.28 and a 200 day moving average price of $27.95.

Insider Activity at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On XOMA

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ellsworth Advisors LLC purchased a new position in XOMA during the third quarter worth about $516,000. Barclays PLC boosted its stake in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Bank of New York Mellon Corp increased its stake in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. State Street Corp lifted its holdings in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.